Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-14
2005-06-14
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S316000
Reexamination Certificate
active
06906081
ABSTRACT:
This invention relates to a method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H3receptor antagonist/m2muscarinic antagonist, or a combination of a histamine H3receptor antagonist and a m2muscarinic antagonist.
REFERENCES:
patent: 2624734 (1953-01-01), Goldberg et al.
patent: 5352707 (1994-10-01), Pompni et al.
patent: 5446057 (1995-08-01), Augelli-Szafran et al.
patent: 5463074 (1995-10-01), Shih et al.
patent: 5578616 (1996-11-01), Aslanian et al.
patent: 5633250 (1997-05-01), Shih et al.
patent: 5807872 (1998-09-01), Shih et al.
patent: 5883096 (1999-03-01), Lowe et al.
patent: 5889006 (1999-03-01), Lowe et al.
patent: 5935958 (1999-08-01), Kozlowski et al.
patent: 5952349 (1999-09-01), Asberom et al.
patent: 5977138 (1999-11-01), Wang et al.
patent: 5990147 (1999-11-01), Aslanian et al.
patent: 6034251 (2000-03-01), Aslanian et al.
patent: 6037352 (2000-03-01), Lowe et al.
patent: 6043255 (2000-03-01), Lowe et al.
patent: 6066636 (2000-05-01), Kozlowski et al.
patent: 6100279 (2000-08-01), Vaccaro et al.
patent: 6294554 (2001-09-01), Clader et al.
patent: 0 420 396 (1991-04-01), None
patent: WO 93/01812 (1993-02-01), None
Drug Facts and Comparisons, 1999 edition, p. 1731.
Craig D. Boyle et al., Bioorganic & Medicinal Chemistry Letters, 10 pp. 2727-2730 (2000).
Stephen L. Yates et al., The Journal of Pharmacology & Experimental Therapeutics, 289 (2), pp. 1151-1159 (1999).
X. Ligneau et al., The Journal of Pharmacology & Experimental Therapeutics 287, (2) pp. 658-666 (1998).
Rob Leurs et al., Elsevier Science Ltd., 19, pp. 177-184 (1998).
Maria Grazia Giovannini et al., Behavioural Brain Research 104, pp. 147-155 (1999).
Susan R. McGurk, Ph.D., J. Clin Psychiatry 60 (suppl 12), pp 24-29 (1999).
Nita Nacasch et al., Clinical Neuropharmacology, 21, (2) pp. 132-134 (1998).
Folia Pharmacol. Jpn., 114, pp. 89-106 (1999)—XP 008021117.
William Howson et al., Bioorg. & Med. Chem. Letters, vol. 2, No. 1, (1992), pp. 77-78.
Van der Goot et al., Eur J. Med Chem (1992) vol. 27, pp. 511-517.
Clapham et al., J. Psychopharmacol. British Assn. For Psychopharmacology, Jul. 25-28, 1993, Asbstr. Book, A17.
Clapham et al., Brit. J. Pharm. Suppl., 1993, 110, Abstr. 65P.
Yokoyama et al, Eur. J. Pharmacol., vol. 234 (1993), pp. 129-133.
Schlicker et al., Br. J. Pharmacol. (1994), 112, pp. 1043-1048.
Leurs et al., Progr. Drug Res. (1992) vol. 39, pp. 127-165.
Lipp et al. The Histamine Receptor, eds.: Schwartz and Haas, Wiley-Liss, New York, (1992), pp. 57-72.
West et al., Molecular Pharmacology, vol. 38, (1990), pp. 610-613.
Korte et al., Biochemical and Biophysical Research Communications, vol. 168, (1990), pp. 979-986.
Aslanian Robert G.
Hey John A.
Hui San-ming
Magatti Anita W.
Schering Corporation
LandOfFree
Use of dual H3/M2 antagonists in the treatment of cognition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of dual H3/M2 antagonists in the treatment of cognition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of dual H3/M2 antagonists in the treatment of cognition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487017